{"id":3251,"date":"2024-06-10T11:22:38","date_gmt":"2024-06-10T15:22:38","guid":{"rendered":"https:\/\/cytel.agencyukdev.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/"},"modified":"2024-08-22T06:06:42","modified_gmt":"2024-08-22T10:06:42","slug":"platform-trials-master-protocols-and-challenges-in-execution","status":"publish","type":"perspectives","link":"https:\/\/cytel.agencyukdev.com\/fr\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/","title":{"rendered":"Platform Trials, Master Protocols, and Challenges in Execution"},"content":{"rendered":"<p>How can we build an efficient statistical protocol for a clinical trial, if we do not know the therapies that will be tested nor the populations on whom the testing will occur? This is the challenge confronting those working to design an ever-increasing number of platform trials. In a recent webinar, Dr. Kyle Wathen, Cytel&#8217;s Vice President of Scientific Strategy and Innovation, discussed a method using platform trials to show how to build such trials.<\/p>\n<p><!--more--><\/p>\n<p><strong>Platform Trials \u2013 A brief overview<\/strong><\/p>\n<p>Trials like I-SPY2, Janssen\u2019s trials on autism spectrum disorder, and a number of COVID therapies, the set of trial designs that fall under the purview of master protocols is growing in number as well as nuance. Basket trials, umbrella trials, and platform trials not only raise design challenges, they all require enhanced operational know-how to adequately measure treatment effect. Still, their value to expediting drug development is unparalleled.<\/p>\n<p>A master protocol can either test a single investigational drug or drug combination in many populations (a basket trial), or many investigational drugs or drug combinations in a single population (an umbrella trial). A platform trial can combine both of these elements to test several investigational therapies in heterogeneous populations where new therapies are added over time via an Intervention Specific Appendix (ISA).<\/p>\n<p>The benefits of a platform trial are that both research infrastructure and data collected can be shared among appropriate investigational therapies. This decreases cost by spreading and scaling resource use, while also providing for more robust analyses. The challenges lie in many areas including statistics, operations, and trial execution, all of which can impact the performance of the design.<\/p>\n<p>A further challenge, examined in a recent webinar by Cytel&#8217;s Dr. Kyle Wathen, is the difficulty of building a protocol, when it is unknown which therapies and populations will eventually be tested using it.<\/p>\n<p><strong>Using Intervention Specific Appendices (ISA) for information sharing<\/strong><\/p>\n<p>Each investigational drug added to a platform trial will have its own ISA, which contains information on both comparator and treatment. As the trials progress, a diagram such as the one above can demonstrate which interventions were being tested and when. This not only provides a simple model for what is being tested, it quickly becomes clear that information sharing between investigational drugs is easiest when ISAs overlaps. When they don\u2019t overlap, careful consideration must be taken in sharing information between non-concurrent ISAs.<\/p>\n<p>A number of quantitative strategies can be used to adjust for borrowing patients across ISAs. It is possible to discount patients enrolled before an ISA began, for example, or create a model for time trends. Hierarchical borrowing is also a possibility, although each of these advanced approaches requires significant statistical expertise.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Building the right randomization strategy for a platform trial<\/strong><\/p>\n<p>Randomization within the context of a platform trial can either be a one- or a two-step strategy. The traditional mode of randomization (the one-step strategy) requires greater screening when directed at a master protocol trial. The two-step strategy for ISAs can raise challenges about informed consent.<\/p>\n<p>In a one-step strategy, a patient is directly randomized to a treatment. Alternatively, patients can first be randomized to an ISA and then to a treatment within the ISA. The two-step solution creates additional flexibility in that either a patient or a site, might be opposed to one or more of the ISAs on a platform. One must carefully consider the trade-offs of either a one-step or two-step approach.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Considerations about statistical analysis plans when implementing platform trials<\/strong><\/p>\n<p>Building SAPs for platform trials raise specific challenges. Statisticians need to be familiar with methods that account for population heterogeneity, and rules for stopping for efficacy and futility have added considerations when compared to more traditional approaches.<\/p>\n<p>Dr. Wathen warns that developing a master protocol approach requires additional considerations and an extensive simulation study in order to fully understand the performance of various options. He also discussed the importance of carefully considering future interventions or subgroups that may be added in order to help avoid potential issues when they are added.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Trial design optimization with platform trials<\/strong><\/p>\n<p>According to Dr. Wathen, designing an efficient platform trial is very similar to designing a number of more traditional trials at once. There is an added feature, of course, that ISAs executed concurrently make data-sharing easier. This means that decision-rules for a given platform likely look quite different than traditional trials and must be thoroughly explored by simulation in the design process to account for this. OCTOPUS (https:\/\/kwathen.github.io\/OCTOPUS\/) , an R-package he developed while at Janssen, can help simulate different platform designs.<\/p>","protected":false},"featured_media":3476,"parent":0,"template":"","meta":{"_acf_changed":false},"tags":[76],"by-topic":[429,461,462],"by-year":[72],"class_list":["post-3251","perspectives","type-perspectives","status-publish","has-post-thumbnail","hentry","tag-blog","by-topic-adaptive-clinical-trials","by-topic-master-protocol","by-topic-platform-trials","by-year-72"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Platform Trials, Master Protocols, and Challenges in Execution - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us<\/title>\n<meta name=\"description\" content=\"Cytel&#039;s Vice President of Scientific Strategy and Innovation, Dr. Kyle Wathen shares how to build an efficient statistical protocol for a clinical trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Platform Trials, Master Protocols, and Challenges in Execution - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"og:description\" content=\"Cytel&#039;s Vice President of Scientific Strategy and Innovation, Dr. Kyle Wathen shares how to build an efficient statistical protocol for a clinical trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-22T10:06:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-12.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/platform-trials-master-protocols-and-challenges-in-execution\\\/\",\"url\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/platform-trials-master-protocols-and-challenges-in-execution\\\/\",\"name\":\"Platform Trials, Master Protocols, and Challenges in Execution - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/platform-trials-master-protocols-and-challenges-in-execution\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/platform-trials-master-protocols-and-challenges-in-execution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Cytel_web_abstract-12.jpg\",\"datePublished\":\"2024-06-10T15:22:38+00:00\",\"dateModified\":\"2024-08-22T10:06:42+00:00\",\"description\":\"Cytel's Vice President of Scientific Strategy and Innovation, Dr. Kyle Wathen shares how to build an efficient statistical protocol for a clinical trial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/platform-trials-master-protocols-and-challenges-in-execution\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/platform-trials-master-protocols-and-challenges-in-execution\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/platform-trials-master-protocols-and-challenges-in-execution\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Cytel_web_abstract-12.jpg\",\"contentUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/Cytel_web_abstract-12.jpg\",\"width\":2048,\"height\":1365},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/platform-trials-master-protocols-and-challenges-in-execution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Platform Trials, Master Protocols, and Challenges in Execution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\",\"name\":\"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\",\"description\":\"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Platform Trials, Master Protocols, and Challenges in Execution - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","description":"Cytel's Vice President of Scientific Strategy and Innovation, Dr. Kyle Wathen shares how to build an efficient statistical protocol for a clinical trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/","og_locale":"fr_FR","og_type":"article","og_title":"Platform Trials, Master Protocols, and Challenges in Execution - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","og_description":"Cytel's Vice President of Scientific Strategy and Innovation, Dr. Kyle Wathen shares how to build an efficient statistical protocol for a clinical trial.","og_url":"https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/","og_site_name":"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","article_modified_time":"2024-08-22T10:06:42+00:00","og_image":[{"width":2048,"height":1365,"url":"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-12.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/","url":"https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/","name":"Platform Trials, Master Protocols, and Challenges in Execution - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","isPartOf":{"@id":"https:\/\/cytel.agencyukdev.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/#primaryimage"},"image":{"@id":"https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/#primaryimage"},"thumbnailUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-12.jpg","datePublished":"2024-06-10T15:22:38+00:00","dateModified":"2024-08-22T10:06:42+00:00","description":"Cytel's Vice President of Scientific Strategy and Innovation, Dr. Kyle Wathen shares how to build an efficient statistical protocol for a clinical trial.","breadcrumb":{"@id":"https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/#primaryimage","url":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-12.jpg","contentUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/Cytel_web_abstract-12.jpg","width":2048,"height":1365},{"@type":"BreadcrumbList","@id":"https:\/\/www.cytel.com\/perspectives\/platform-trials-master-protocols-and-challenges-in-execution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cytel.agencyukdev.com\/"},{"@type":"ListItem","position":2,"name":"Platform Trials, Master Protocols, and Challenges in Execution"}]},{"@type":"WebSite","@id":"https:\/\/cytel.agencyukdev.com\/#website","url":"https:\/\/cytel.agencyukdev.com\/","name":"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","description":"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cytel.agencyukdev.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives\/3251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives"}],"about":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/types\/perspectives"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media\/3476"}],"wp:attachment":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media?parent=3251"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/tags?post=3251"},{"taxonomy":"by-topic","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-topic?post=3251"},{"taxonomy":"by-year","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-year?post=3251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}